$CAH (Cardinal Health, Inc.)

$CAH {{ '2016-02-16T17:35:26+0000' | timeago}} • SEC

$CAH's amortization of acquisition-related intangible assets was $100MM in 2Q16 versus $47MM in 2Q15. The increase was largely due to the acquisitions of Cordis and Harvard Drug. Transaction and integration costs associated with the acquisition of Cordis were $20MM and $41MM during 2Q16 and 1H16, respectively.

$CAH {{ '2017-11-15T12:47:08+0000' | timeago}} • Announcement

$CAH has agreed to sell its China business to Shanghai Pharmaceuticals Holding Co., Ltd. for $1.2Bil. The sale includes the company’s pharmaceutical and medical products distribution business in China. The transaction is expected to close by the end of Cardinal Health's fiscal year.

$MDT {{ '2017-11-09T13:05:42+0000' | timeago}} • Announcement

Preliminary 2Q18 Results: $MDT worldwide revenue declined 4% to approx. $7.05Bil, with the decline driven by the company's divestiture of its Patient Care, Deep Vein Thrombosis and Nutritional Insufficiency businesses to $CAH. The company expects the impact of Hurricane Maria to be approx. $0.03 to non-GAAP EPS for 2Q18.

$CAH {{ '2017-11-08T22:19:14+0000' | timeago}} • Announcement

$CAH has declared a regular quarterly dividend of $0.4624 per share on its common stock. The dividend is payable on January 15, 2018, to shareholders of record on January 2, 2018.

$CAH {{ '2017-11-06T13:31:29+0000' | timeago}} • Infographic

$CAH Cardinal Health Earnings AlphaGraphic: Q1 2018 Highlights

$CAH {{ '2017-11-06T13:18:54+0000' | timeago}} • Announcement

Healthcare services company $CAH has appointed Mike Kaufmann as CEO, to succeed George Barrett. Kaufmann, who currently serves as CFO, will also join the company’s board of directors, effective January 1, 2018. Jorge Gomez will succeed Kaufmann as CFO, while Barrett will continue to serve as executive chairman of the BoD until November 2018.

$CAH {{ '2017-11-06T12:40:22+0000' | timeago}} • Announcement

$CAH reaffirmed its FY18 non-GAAP EPS guidance of $4.85-5.10. CEO George Barrett said fiscal 2018 started largely as the company expected and included strong performance from many of its business lines across the segments.

$CAH {{ '2017-11-06T12:39:09+0000' | timeago}} • Announcement

$CAH's revenue from the Medical segment for 1Q18 grew 14% from last year. This was primarily driven by contributions from acquisitions and, to a lesser extent, new and existing customers. Segment profit rose 1% on contributions from acquisitions, which were mostly offset by the reduced contribution from a Veterans Affairs contract.

$CAH {{ '2017-11-06T12:38:36+0000' | timeago}} • Announcement

$CAH's revenue from the Pharmaceutical segment for 1Q18 rose 1% from last year. This was due to sales growth from specialty and pharmaceutical distribution customers, which was partially offset by the previously announced May 2017 expiration of a large, mail-order customer contract.

$CAH {{ '2017-11-06T12:38:22+0000' | timeago}} • Announcement

$CAH reported a 62% plunge in 1Q18 earnings due to restructuring costs from regaining direct distribution of self-manufactured surgeon gloves and higher intangible assets amortization. Net income fell to $117MM or $0.36 per share from $310MM or $0.96 per share last year. Revenue rose 2% to $32.64Bil. Non-GAAP EPS decreased 12% to $1.09.

$CAH {{ '2017-08-09T20:21:11+0000' | timeago}} • Announcement

$CAH has declared a quarterly dividend of $0.4624 per share. The dividend is payable on October 15, 2017, to shareholders of record on October 2, 2017.

$CAH {{ '2017-07-31T12:06:51+0000' | timeago}} • Announcement

$CAH closed purchase of $MDT's Patient Care, Deep Vein Thrombosis and Nutritional Insufficiency business for $6.1Bil. The acquisition was funded with a combination of $4.5Bil in new senior unsecured notes, existing cash and borrowings under $CAH's existing credit arrangements.

$MDT {{ '2017-07-31T12:02:15+0000' | timeago}} • Announcement

$MDT completes the sale of its Patient Care, Deep Vein Thrombosis (Compression), and Nutritional Insufficiency businesses within the Patient Monitoring & Recovery division to $CAH for $6.1Bil in cash. The company expects modest dilution on a net basis to its FY18 non-GAAP EPS of approx. $0.18.

$MDT {{ '2017-05-25T11:22:16+0000' | timeago}} • Announcement

In FY18, $MDT expects constant currency revenue growth to be in the range of 4% to 5%. Medtronic sees full-year non-GAAP diluted EPS to grow by 9-10%. Fiscal year guidance does not include the impact of the divestiture of a portion of its Patient Monitoring and Recovery division to $CAH, expected to close in 2Q18.

$CAH {{ '2017-05-03T21:40:57+0000' | timeago}} • Announcement

$CAH BoD approved a 3% increase in quarterly dividend from $0.4489 per share to $0.4624 per share. The dividend is payable on July 15 to shareholders of record on July 3.

$CAH {{ '2017-05-01T19:40:41+0000' | timeago}} • Webcast

$CAH expects closer to 90% of its branded agreements, currently over 85%, to be non-contingent to inflation by FY17 end, if not by the end of FY18.

$CAH {{ '2017-05-01T18:58:25+0000' | timeago}} • Webcast

$CAH sees to incur tax and some reserve adjustments in FY17 but not in FY18. Cardinal Health also expects incremental expenses over the next couple of years due to the planned Pharma Distribution IT refresh project rollout, particularly next year.

$CAH {{ '2017-05-01T11:44:43+0000' | timeago}} • Announcement

3Q17 revenue for the Pharmaceutical segment rose 3% to $28.4Bil at $CAH, due to the performance from the Specialty business and growth from Pharmaceutical Distribution customers. Medical segment revenue was up 9% to $3.4Bil. CAH now sees FY17 non-GAAP EPS from continuing ops at the bottom of its previous guidance range of $5.35-5.50.

$CAH {{ '2017-05-01T11:43:33+0000' | timeago}} • Announcement

$CAH's revenue inched 4% up to $31.8Bil in 3Q17, as the health care services company's net income slipped 1% to $381MM from last year's $386MM. Earnings rose 3% to $1.20 per diluted share from last year's $1.17 a share, benefitted from a lower effective tax rate and fewer weighted average shares outstanding.

$CAH {{ '2017-04-19T12:13:05+0000' | timeago}} • Announcement

$CAH expects generic deflation to moderate to mid-single digits in FY18 but this deflation is still a headwind for the Pharmaceutical segment for the year.  This, combined with certain discrete items could result in an estimated Pharmaceutical segment profit decline in the high-single digits versus FY17.

$CAH {{ '2017-04-19T12:12:44+0000' | timeago}} • Announcement

For FY18, $CAH expects adjusted EPS to be flat to down mid-single digits. $CAH also expects a significant increase in the Medical segment's profit. $CAH believes certain company-specific discrete items will have a negative impact on EPS of at least $0.50. For FY19, $CAH expects adjusted EPS to grow at least high-single digits vs. FY18.

Recent Transcripts

OPK (Opko Health, Inc.)
Wednesday, November 8 2017 - 9:30pm
HUM (Humana Inc.)
Wednesday, November 8 2017 - 2:00pm
REGN (Regeneron Pharmaceuticals, Inc.)
Wednesday, November 8 2017 - 1:30pm
ATRS (Antares Pharma Inc.)
Tuesday, November 7 2017 - 1:30pm
VRX (Valeant Pharmaceuticals International, Inc.)
Tuesday, November 7 2017 - 1:00pm
CAH (Cardinal Health, Inc.)
Monday, November 6 2017 - 1:30pm
HLF (Herbalife Ltd.)
Thursday, November 2 2017 - 9:30pm
HSKA (Heska Corporation)
Thursday, November 2 2017 - 3:00pm
AME (Ametek Inc.)
Thursday, November 2 2017 - 12:30pm
ABC (AmerisourceBergen Corporation)
Thursday, November 2 2017 - 12:30pm
BDX (Becton, Dickinson and Company)
Thursday, November 2 2017 - 12:00pm
NUS (Nu Skin Enterprises Inc.)
Wednesday, November 1 2017 - 9:00pm
AMRN (Amarin Corporation plc)
Wednesday, November 1 2017 - 12:00pm
AGIO (Agios Pharmaceuticals, Inc.)
Wednesday, November 1 2017 - 12:00pm
ACOR (Acorda Therapeutics, Inc.)
Tuesday, October 31 2017 - 12:30pm
IDXX (IDEXX Laboratories, Inc.)
Tuesday, October 31 2017 - 12:30pm
MSFT (Microsoft Corporation)
Thursday, October 26 2017 - 9:30pm
IART (Integra LifeSciences Holdings Corporation)
Thursday, October 26 2017 - 12:30pm
MCK (McKesson Corporation)
Thursday, October 26 2017 - 12:00pm
ABAX (Abaxis, Inc.)
Tuesday, October 24 2017 - 8:15pm

AlphaGraphics you may like